STOCKHOLM, Sweden--(BUSINESS WIRE)--(OMX Nordic List, Mid Cap: ORX) HealthCap, a leading venture capital investor in life sciences and the largest shareholder in Orexo, today confirms that, it will not transfer its Orexo shares without the prior written consent of ABG Sundal Collier, which consent shall not be unreasonably withheld, for a period of 12 months from the closing of the previously announced acquisition of Biolipox AB by Orexo.
